This is an extremely rare event that was nonetheless detected by scientists who then nonetheless updated dosing guidelines to mitigate it as early as February 2022.
This has been an active area of focus since before the drugs were even released which is why such events were in fact tracked closely during the 30,000+ participant clinical trials.
Those gigantic clinical trials (some of the largest RCTs ever conducted) didn't detect this issue because of its extreme rarity.
This is exactly the drug development and post-market surveillance process working correctly. At every point (and even still) the risk calculus is heavily weighted toward vaccination for nearly everyone, and slightly weighted toward vaccination for the most SAE-prone group (young men).
And that's all assuming COVID doesn't have latent systemic effects like many viruses do (chickenpox, ebola, or measles come to mind).
The skeptics have been wrong at every turn. It's even too generous to say a broken clock is right twice a day.